Open Interest and Volume Dynamics
The latest data reveals that Aurobindo Pharma's open interest jumped by 9,181 contracts, a notable 19.83% increase, signalling heightened participation in the stock’s futures and options market. The volume for the day stood at 20,797 contracts, supporting the OI expansion and indicating fresh positions being established rather than existing ones being squared off.
Futures value traded was ₹81,442.79 lakhs, while options turnover was substantially higher at ₹9,188.47 crores, culminating in a total derivatives turnover of ₹82,548.93 lakhs. This level of activity underscores the stock’s liquidity and attractiveness to traders seeking exposure through derivatives instruments.
Price Action and Moving Averages
On the price front, Aurobindo Pharma hit a new 52-week high of ₹1,530 on 19 May 2026, outperforming its sector by 0.25% and the Sensex by 0.96%. The stock is trading comfortably above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a sustained uptrend and strong technical momentum.
Such price strength alongside rising open interest typically points to fresh buying interest and confidence among institutional and retail investors alike.
Market Positioning and Directional Bets
The surge in open interest, combined with rising prices and volume, suggests that market participants are positioning for further upside in Aurobindo Pharma. The increase in OI is often interpreted as new money flowing into the market, with traders taking bullish futures and call option positions.
Interestingly, despite the strong derivatives activity, delivery volumes have declined by 26.51% to 5.02 lakh shares on 18 May compared to the 5-day average. This divergence may indicate that traders are favouring leveraged derivatives exposure over outright cash market purchases, possibly to capitalise on expected volatility or to hedge existing positions.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Fundamental and Market Context
Aurobindo Pharma, a mid-cap pharmaceutical and biotechnology company with a market capitalisation of ₹87,820 crores, has been steadily improving its market positioning. The company’s Mojo Score stands at 72.0, upgraded from a previous Hold rating to a Buy on 24 March 2026, reflecting enhanced fundamentals and positive outlook.
The stock’s ability to outperform its sector and broader indices on a day of strong derivatives activity highlights investor confidence in its growth prospects amid a competitive pharmaceutical landscape.
Liquidity and Trading Considerations
Liquidity remains robust, with the stock’s traded value supporting a trade size of approximately ₹3.76 crores based on 2% of the 5-day average traded value. This ensures that institutional investors can enter or exit sizeable positions without significant market impact, further encouraging active participation in both cash and derivatives markets.
Given the current technical and derivatives market signals, traders may consider Aurobindo Pharma as a favourable candidate for bullish strategies, including long futures and call options, while monitoring for any shifts in delivery volumes or volatility that could affect positioning.
Want to dive deeper on Aurobindo Pharma Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Implications for Investors
The pronounced increase in open interest and volume in Aurobindo Pharma’s derivatives market is a clear indicator of growing bullish sentiment. Investors should note that such activity often precedes significant price moves, as fresh capital flows into the stock.
However, the decline in delivery volumes suggests a cautious approach among some participants, possibly reflecting profit booking or hedging strategies. This mixed signal warrants close monitoring of subsequent trading sessions to confirm the sustainability of the current uptrend.
Overall, the upgraded Mojo Grade to Buy and the stock’s strong technical positioning make Aurobindo Pharma a compelling option for investors seeking exposure to the pharmaceuticals and biotechnology sector, especially given its mid-cap status and improving fundamentals.
Looking Ahead
Market participants should watch for continued open interest growth and price momentum as confirmation of sustained bullish positioning. Additionally, tracking option chain data for shifts in put-call ratios and strike price concentrations can provide further insights into market expectations.
Given the current data, Aurobindo Pharma appears well poised to capitalise on sector tailwinds and investor optimism, making it a stock to watch closely in the coming weeks.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
